Stifel analyst Stephen Willey lowered the firm’s price target on AbCellera (ABCL) to $8 from $10 and keeps a Buy rating on the shares. The firm views the unveiling of NK3R as the target of ABCL635 ahead of the Phase 1 trial initiation as “an interesting development which positions ABCL635 as a more-selective/likely-safer and more-convenient treatment option,” the analyst tells investors following management’s earnings announcement and corporate update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABCL: